PROSTATE CANCER

This study tests whether giving an extra-high radiation dose directly to the main prostate tumor, along with standard radiation to the rest of the prostate, can cure intermediate-risk prostate cancer or keep it from coming back longer. About 91 men with intermediate-risk prostate…

This early-stage study tests a personalized vaccine (PGV001) combined with an immune booster (CDX-301) in 27 men who have had aggressive prostate cancer but currently show no signs of tumor. The goal is to see if the vaccine is safe and can train the immune system to recognize an…

This study was designed for men with low-volume metastatic hormone-sensitive prostate cancer. It planned to compare two treatment combinations: one with two drugs (ADT plus abiraterone) and another with three drugs (adding docetaxel). The goal was to see which approach better del…

This study tests an experimental radioactive drug, 225Ac-PSMA-R2, in men with advanced prostate cancer that has spread. The drug seeks out and delivers radiation directly to cancer cells. The trial includes men whose cancer has stopped responding to hormone therapy and who have o…

This study tests whether adding a new drug (LY2157299) to the standard treatment enzalutamide can help men with advanced prostate cancer that has stopped responding to other treatments. About 60 participants will be randomly assigned to receive either the combination or enzalutam…

This study aimed to see if a person's race changes how well a combination of two drugs (niraparib and abiraterone acetate plus prednisone) works for a certain type of advanced prostate cancer. It planned to enroll Black, Hispanic, White, and Native American men whose cancer had s…

This study aimed to see if a precise, high-dose radiation treatment (HDR brachytherapy) could safely control prostate cancer that returned only in the prostate gland after initial radiation. It planned to enroll men whose cancer was detected by a special PET scan and confirmed by…

This phase 3 trial compares enzalutamide alone versus enzalutamide plus radium-223 (Ra223) in 446 men with castration-resistant prostate cancer that has spread to bones but causes few or no symptoms. The goal is to see if the combination delays cancer progression on scans. Partic…

This study tests a special coffee made from the Artemisia annua plant (ArtemiCoffee) in 20 men whose prostate cancer has returned after initial treatment, shown by rising PSA levels. The goal is to see if drinking this coffee can lower PSA by at least 50% within 24 weeks. It is a…

This study tests a drug called 177Lu rhPSMA-10.1, which delivers radiation directly to prostate cancer cells. It is given alone or with hormone therapy to men with high-risk localized prostate cancer before they have surgery to remove the prostate. The goal is to see if the drug …

This study planned to test whether surgeons could safely operate a robot from far away to treat prostate cancer. It was designed for adults needing robotic prostate surgery. However, the trial was withdrawn before any patients joined, so no results are available.

This study tests a powerful mix of hormone therapy, a targeted drug (niraparib), and precise radiation in men with high-risk or node-positive prostate cancer. The goal is to find the safest dose and see if this approach can keep PSA levels low for three years. About 100 men are p…

This study tests a two-step treatment plan for men with high-risk prostate cancer that has spread. First, patients receive hormone therapy plus a newer drug, followed by chemotherapy. The goal is to improve survival by attacking the cancer in a way that makes it harder for it to …

This study tests whether a shorter course of hormone therapy (ADT) combined with two types of radiation (brachytherapy and external beam) can safely prevent high-risk prostate cancer from coming back or spreading. About 50 men with aggressive prostate cancer and a favorable genet…

This study tests a treatment plan for men with aggressive prostate cancer that combines hormone therapy with two types of radiation: external beam radiation and an internal implant (brachytherapy). The goal is to see if this approach causes fewer side effects while still controll…

This study tests a new treatment called 177Lu-PSMA-617, which delivers radiation directly to prostate cancer cells, against standard chemotherapy (docetaxel) in 200 men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The goal is to se…

This study compares a new hormone therapy (darolutamide) plus radiation against standard hormone therapy plus radiation for men with intermediate-risk prostate cancer. The goal is to see if the new approach works just as well at controlling the cancer while also helping men keep …

This study tested whether a shorter, more intense course of radiation (5 sessions) works as well as the standard longer course (26 sessions) for prostate cancer. It involved 161 men with early-stage prostate cancer. The main goal was to see if the shorter treatment controls the c…

This study is for men with advanced prostate cancer that has spread and is no longer controlled by hormone therapy. Researchers are testing a drug called 177Lu-PSMA-617, which delivers radiation directly to cancer cells. The goal is to find the highest dose that can be given safe…

This study tests whether giving an extra-high dose of radiation to the most aggressive parts of prostate tumors, guided by MRI scans, can improve cancer control while protecting nearby organs. About 164 men with prostate cancer will receive either this boost plus standard radiati…

This study tests a drug called palbociclib in men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth, and to monitor side effects. About 19 participants will rec…

This study tests whether adding a second DNA vaccine to a standard immunotherapy (pembrolizumab) can help men with advanced prostate cancer that no longer responds to hormone therapy. About 60 participants will receive either one or two DNA vaccines plus pembrolizumab for up to t…

This study uses advanced MRI scans to guide radiation therapy for men with localized prostate cancer. Depending on whether a tumor is visible on the MRI, patients receive either a short course of radiation to the whole prostate or a longer treatment that boosts the dose to the tu…

This study tests whether combining an experimental targeted radiation drug (177Lu-J591) with hormone therapy (ketoconazole) can keep prostate cancer from spreading in men whose cancer has returned after initial treatment. About 55 men with high-risk, castration-resistant prostate…

This study tests a low dose of a radioactive drug called 225Ac-LNC1011 in 16 men with a type of advanced prostate cancer that has stopped responding to hormone therapy. The drug targets a protein (PSMA) found on cancer cells to deliver radiation directly to tumors. The main goals…

This study compares a new oral drug, darolutamide, to standard hormone therapy (ADT) in men with prostate cancer that still responds to hormones. About 250 men will be randomly assigned to receive either the pill or injections. The main goal is to see if the pill can lower PSA le…

This study tests an experimental oral drug, MRT-2359, in people with certain advanced cancers, including lung cancer and lymphoma, that are driven by MYC genes. The trial has two phases: first, finding a safe dose, and second, checking if the drug shrinks tumors. About 174 adults…

This study compares a new, ultra-short radiation schedule (5 treatments) against the standard longer course for prostate cancer that has spread to lymph nodes. About 500 men will receive either the short or standard radiation, plus a brachytherapy boost and hormone therapy. The g…

This study compares three types of radiation therapy for prostate cancer to find which one controls the cancer best while causing the fewest side effects. About 500 men with prostate cancer are taking part. The goal is to improve treatment by testing different ways of delivering …

This early-phase trial tests an experimental drug called [Ac-225]-PSMA-62 in men with prostate cancer that has spread and is no longer responding to standard treatments. The drug delivers a radioactive payload directly to cancer cells that have a specific marker (PSMA). The study…

This study tests a new way to deliver extra radiation directly to prostate tumors using a 3D ultrasound guidance system. Fifteen men with low- or favorable intermediate-risk prostate cancer will receive standard brachytherapy plus up to 4 additional iodine-125 implants placed pre…

This study tests a precise type of proton radiation for men with low- or intermediate-risk prostate cancer. The goal is to see if this approach causes fewer severe urinary and bowel side effects than standard X-ray-based radiation. About 61 men will receive 5 treatments over 10 d…

This study looked at men with prostate cancer that is at moderate to high risk of coming back. It compared standard treatment (hormone therapy plus high-dose radiation to the prostate) against the same treatment plus radiation to the whole pelvis. The goal was to see if the extra…

This study tests whether giving a higher dose of radiation to the exact spot where prostate cancer has returned (seen on an MRI) can better lower PSA levels in men who have already had their prostate removed. 37 men with a rising PSA after surgery are participating. The goal is t…

This study compares a standardized active surveillance protocol to usual care for men with low-risk prostate cancer. The goal is to see if a clear plan for repeat biopsies and treatment triggers can reduce overtreatment and side effects without increasing the risk of cancer sprea…

This study tests a new way to deliver radiation to the prostate and nearby lymph nodes in men with high-risk or unfavorable intermediate-risk prostate cancer. The approach uses MRI to find the exact tumor location and gives a higher dose there. The goal is to see if this method i…

This study checks the long-term safety of a balloon implant used during radiation therapy for prostate cancer. It follows 80 patients who already had the implant to see if they have any bowel or urinary side effects over time. The goal is to make sure the device is safe and helps…

This study looks at whether taking omega-3 (EPA) supplements can reduce inflammation and improve quality of life in men with high-risk prostate cancer who have their prostate removed. About 130 participants will take either fish oil capsules or placebo for six weeks before surger…

This study compares two drugs, mannitol and nitroglycerin, given during robotic prostate or bladder cancer surgery to see if they can prevent acute kidney injury. The surgery uses gas to inflate the belly, which can reduce blood flow to the kidneys. The trial includes 90 adults w…

This early-phase study is testing whether combining a targeted radioactive drug (177Lu-PSMA617) with precise radiation therapy (SBRT) is safe for men with hormone-sensitive prostate cancer that has spread to a few spots in the body. The goal is to see if this approach can delay t…

This study tests a device that uses water vapor (steam) to destroy prostate cancer tissue in men with intermediate-risk prostate cancer. About 400 men aged 50 and older will receive the treatment and be followed for safety and cancer control. The goal is to avoid more aggressive …

This early-phase study tests two ultra-high-dose radiation schedules (5 sessions or 1 session) in 31 men with intermediate-risk prostate cancer. The goal is to see if these intense, precise treatments are safe and can control the cancer. Participants will be followed for at least…

This study looks at whether aerobic exercise can lower ctDNA levels in the blood, which may help prevent cancer from returning. About 33 people who have been treated for high-risk breast, prostate, or colorectal cancer will try different amounts of weekly exercise to find the saf…

This early-phase study tests whether a patient's own immune cells can be genetically modified to recognize and attack prostate cancer cells. Thirteen men with advanced prostate cancer that no longer responds to hormone therapy will receive their own altered T cells. The main goal…

This early-phase study tests a new oral drug, MOMA-313, alone or with another drug (olaparib) in people with advanced solid tumors that have a specific DNA repair problem (HR deficiency). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. …

This study tests an experimental drug called AZD5305, a PARP inhibitor, in people with advanced solid tumors (e.g., ovarian, breast, prostate, lung cancer). The goal is to see if the drug is safe and can shrink tumors when given alone or with other anti-cancer medicines. About 70…

This study tests whether adding the drug abemaciclib to standard hormone therapy (abiraterone and prednisone) can slow the growth of advanced prostate cancer that has spread to other parts of the body. About 393 men with this type of cancer will take part. The main goal is to see…

This study tests if a shorter course of proton radiation (5 treatments over 1-2 weeks) works as well as the standard longer course (44 treatments over 8-9 weeks) for men with low-risk prostate cancer. About 150 men took part. The goal is to see if the shorter treatment controls t…

This early-stage study tests a new treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack the cancer while resisting t…

This study tests whether a new tracking system (Calypso) that follows the prostate's movement during radiation can reduce long-term side effects compared to standard image-guided radiation. About 74 men with low- or intermediate-risk prostate cancer will take part. The goal is to…

This study looks at whether removing the prostate and nearby lymph nodes, along with standard treatments, helps men with prostate cancer that has spread to a few bones live longer and delay the cancer becoming resistant to hormone therapy. About 452 men with intermediate- or high…

This study tracks the safety and effectiveness of darolutamide in men with prostate cancer that has not spread but is no longer responding to standard hormone therapy. Over 800 participants are being observed in real-world clinics to see how well the drug works and what side effe…

This early-stage study tests two oral drugs, darolutamide and abemaciclib, plus standard hormone therapy in men with high-risk prostate cancer that has spread or may come back. The first part finds the safest dose; the second checks if the combo can shrink tumors before surgery. …

This study is for men with intermediate-risk prostate cancer. It combines two types of radiation: a short internal treatment (brachytherapy) followed by three weeks of highly focused external radiation (SBRT). The goal is to find the safest dose and schedule for this combination.…

This study tested whether adding enzalutamide to standard hormone therapy (leuprolide) can delay the spread of prostate cancer in men with high-risk disease that has not yet spread. Over 1,000 men whose cancer progressed after initial treatment (surgery or radiation) participated…

This study looks at giving a short, precise course of radiation before surgery to remove the prostate in men with high-risk prostate cancer. The goal is to see if this approach is safe and helps control the disease better. Sixteen men with aggressive prostate cancer (Gleason scor…

This study tests if a very short course of radiotherapy (5 treatments over 2 weeks) causes similar bowel and urinary side effects as a standard shorter course (20 treatments over 4 weeks) in men whose prostate cancer has returned after prostate removal. About 134 men will partici…

This study looks at whether adding sunitinib to hormone therapy can shrink or control high-risk prostate cancer before surgery to remove the prostate. About 64 participants will receive the combination treatment, then have their prostate removed to check for complete tumor disapp…

This study looks at how safe and effective a new robotic surgery system (Medtronic Hugo) is for removing cancers of the prostate, bladder, or kidney. About 144 adults who need these surgeries will take part. The main goal is to see if the surgery can be completed without switchin…

This study looks at whether a 16-week home-based exercise program can slow prostate cancer in Black men who are monitoring their cancer without immediate treatment. About 68 men will take part. The program involves high-intensity interval training (HIIT) done virtually with a coa…

This study tests a new approach for men with intermediate-risk prostate cancer. First, doctors use a special electric pulse (IRE) to destroy tumor cells, then follow up with precise radiation (MRgRT). The goal is to see if this combination is safe and can keep cancer away for at …

This study tested whether a targeted chemotherapy drug (abemaciclib) alone or combined with an immunotherapy drug (atezolizumab) can shrink or slow advanced prostate cancer that no longer responds to hormone therapy. 19 men with metastatic castration-resistant prostate cancer too…

This study tests a new long-acting injection called Debio 4228 for men with advanced prostate cancer. The drug blocks a hormone that tells the body to make testosterone, which can fuel cancer growth. The goal is to find the right dose that safely lowers testosterone levels to slo…

This study compares two types of radiation therapy for men with low- or intermediate-risk prostate cancer. One is a shorter, high-dose treatment (SBRT) and the other is a longer, standard treatment (IMRT). The goal is to see which one better maintains quality of life and controls…

This study is for people with high-risk prostate cancer who need stronger radiation. It tests a precise, high-dose radiation method called SABR to the prostate and pelvic area. The goal is to find the highest safe dose while tracking side effects, tumor response, and quality of l…

This study tests a new way of giving hormone therapy for stage IV prostate cancer that has not yet stopped responding to hormones. Instead of continuous treatment, the therapy is given in cycles based on PSA levels. The goal is to keep the cancer under control while reducing side…

This study tests whether combining two drugs (atezolizumab and tivozanib) can help the immune system attack cancers that usually don't respond to immunotherapy, like certain prostate, pancreatic, and breast cancers. About 29 adults with advanced or metastatic disease who have alr…

This early-phase study tests whether giving higher doses of radiation to the prostate in fewer sessions is safe for men with intermediate- to high-risk prostate cancer. The treatment also targets nearby lymph nodes. The main goal is to find a schedule that limits severe side effe…

This study tests a new approach called extreme bipolar androgen therapy (ExBAT) for men with a hard-to-treat type of advanced prostate cancer. It combines a standard drug (darolutamide) with high doses of testosterone to try to control the cancer. The study includes 51 men and ai…

This study looks at two common treatments for prostate cancer that has not spread outside the organ: surgery to remove the prostate and radiation therapy. Researchers want to see which one better controls the cancer and prevents it from coming back. The study will review past rec…

This study tests a new way to deliver high-dose radiation (SABR) for low- and intermediate-risk prostate cancer. The approach spares the urethra, rectum, and pudendal artery to potentially reduce urinary and bowel side effects. About 42 men will receive this treatment and be foll…

This study is for men whose prostate cancer has returned after surgery, shown by a rising PSA. It compares standard hormone therapy plus radiation to a stronger version that adds enzalutamide. The goal is to see if the enhanced treatment keeps the cancer from progressing longer. …

This study tests a new drug called PF-07220060 in people with advanced solid tumors, including breast, prostate, lung, and liposarcoma cancers. The drug is given alone or with hormone therapies to see if it is safe and works well. About 362 participants will take part to find the…

This study tests a precise radiation approach for men with unfavorable prostate cancer. It combines two advanced techniques guided by MRI to target tumors while sparing healthy tissue. The goal is to keep cancer under control for at least 5 years in most participants and reduce s…

This study tests if placing permanent radioactive seeds directly into the prostate (brachytherapy) can control intermediate risk prostate cancer without needing other treatments like hormone therapy or external radiation. Researchers will track PSA levels to see how well the canc…

This study tests whether adding the drug talazoparib to standard hormone therapy (enzalutamide) can slow cancer growth better than hormone therapy alone in men with advanced prostate cancer that has spread and has a specific DNA repair mutation. About 600 men with this genetic ty…

This study tests whether giving a combination of two drugs (leuprorelin and darolutamide) before prostate removal surgery can shrink tumors more effectively than either drug alone. It involves 144 men with intermediate to high-risk prostate cancer who will receive one or both dru…

This study tests a new drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 125 adults with cancers like glioblastoma, melanoma, breast, or prostate ca…

This early-phase study tests whether a one-time injection of lidocaine and alcohol around the prostate can block nerve signals that help cancer grow. It includes 12 men with high-risk localized prostate cancer who have not yet had treatment. The main goal is to find a safe dose a…

This study looks at the safety of the drug TALZENNA in men with a specific type of advanced prostate cancer that has a BRCA gene change and no longer responds to hormone therapy. Only one participant will be enrolled and followed for up to 12 months to track any side effects. The…

This early-phase study tests a new combination of two drugs that deliver radiation directly to prostate cancer cells. The goal is to find the safest dose for men with advanced prostate cancer that has stopped responding to hormone therapy. About 20 participants will receive both …

This study tests whether adding the drug darolutamide to surgery can help men with high-risk or locally advanced prostate cancer. About 240 participants will either have surgery alone or receive darolutamide before and after surgery. The goal is to see if the drug delays cancer f…

This study looks at whether a Mediterranean diet is safe and doable for 25 men with prostate cancer who are treated at a safety-net hospital. The men are Hispanic or Black/African American and have early-stage cancer. Researchers will track side effects and how well participants …

This study compares two types of radiation therapy for prostate cancer: proton therapy and standard photon therapy (IMRT). Researchers are tracking quality of life, side effects, and cancer control in 3000 men over time. The goal is to see if one approach causes fewer bowel or ur…

This study tests a drug called 225Ac-J591, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The first part finds a safe dose, and the second part checks if the drug l…

This study tests a new treatment for men with prostate cancer that has spread to a few other places in the body. The treatment combines targeted radiation with hormone therapy and a drug called olaparib. The goal is to see if this approach can stop the cancer from growing for at …

This study tested whether adding enzalutamide to standard hormone therapy and chemotherapy could better control metastatic prostate cancer. Forty men with hormone-sensitive prostate cancer that had spread took part. The goal was to see if the triple combination was safe and more …

This study aimed to test two experimental drugs, AAA602 and AAA802, given before surgery to remove the prostate in men with high-risk localized prostate cancer. The goal was to see if these drugs could reduce cancer before surgery and delay cancer return. However, the study was w…

This study looks at whether a special gene test can help men with low-risk prostate cancer safely choose active surveillance (watching the cancer closely) instead of immediate treatment like surgery or radiation. About 800 men with early-stage prostate cancer are taking part. The…

This study looks at a faster type of radiation called SBRT for men with prostate cancer that hasn't spread. Instead of 42-45 daily treatments, SBRT delivers higher doses in just 5 sessions. Researchers are tracking how well it controls the cancer and what side effects men experie…

This program offers expanded access to NanoPac, a cancer treatment, for people with advanced pancreatic, prostate, or lung cancer who do not qualify for current clinical trials. The goal is to provide the drug to patients who have no other good treatment options. However, this pr…

This study tests a new type of radiation therapy for men with intermediate-risk prostate cancer. The treatment uses very high doses over fewer sessions, guided by MRI for precision. The goal is to see if this approach is safe and feasible, with 35 participants being monitored for…

This study tests whether a daily dose of green tea catechins (a natural compound) can prevent low- to intermediate-risk prostate cancer from getting worse in men who are not receiving immediate treatment. Over two years, 115 men on active surveillance will receive either the gree…

This study tested whether adding the drug apalutamide to standard hormone therapy (ADT) helps men with prostate cancer that has spread to other parts of the body. Over 1,000 participants were randomly assigned to receive either apalutamide plus ADT or a placebo plus ADT. The goal…

This early-phase study tests two experimental immunotherapy drugs (botensilimab and balstilimab) in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. About 499 participants with various can…

This study tests a new drug called xaluritamig in about 50 men whose prostate cancer has returned after surgery or radiation but has not spread. The main goal is to check the drug's safety and side effects. Researchers will also measure how well it controls PSA levels, a marker o…

This study tests whether a very short course of MRI-guided radiation therapy (just 5 sessions) is safe and effective for men with low- to early high-risk prostate cancer. Standard radiation can take 7-8 weeks, but this approach aims to reduce that time dramatically. The trial inc…

This study compares the effects of a whole-food plant-based diet versus standard nutritional counseling on weight in overweight or obese men with prostate cancer who are receiving hormone therapy (androgen deprivation therapy). About 76 participants will be followed for up to 26 …

This study compares two robot-assisted surgical techniques for removing the prostate in men with intermediate- or high-risk prostate cancer. The goal is to see which approach better preserves urinary control and erectile function while effectively removing cancer. About 118 parti…

This study looks at whether testosterone levels return to normal after two years of treatment with relugolix and darolutamide in men with hormone-sensitive prostate cancer. About 33 participants will take the drugs for two years, then stop to see if their testosterone recovers. T…

This study tests whether combining two drugs, olaparib and AZD6738, can shrink tumors or lower PSA levels in men with advanced prostate cancer that no longer responds to hormone therapy. About 49 men with metastatic castration-resistant prostate cancer will receive the drug combi…

This study is for men with very high-risk or early-spread prostate cancer. It combines hormone-lowering injections, study drugs (abiraterone, prednisone, apalutamide), surgery, and possibly radiation to shrink the cancer as much as possible before surgery. The goal is to lower PS…

This study tests a laser device that destroys prostate cancer tumors using heat, guided by ultrasound instead of MRI. About 30 men with low- to intermediate-risk prostate cancer that hasn't spread will receive this focal treatment. The goal is to see if ultrasound guidance is pra…

This study tests whether adding the immunotherapy drug nivolumab to standard radiation and hormone therapy is safe and can delay the progression of a very aggressive type of prostate cancer (Gleason grade group 5). About 44 men with this high-risk cancer who have not yet received…

This study tests whether adding a chemotherapy drug called carboplatin to a targeted radiation treatment (177Lu-PSMA-617) is safe and effective for men with advanced prostate cancer that no longer responds to hormone therapy. About 37 participants will receive the combination to …

This early-phase study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors, including bladder, breast, lung, and other cancers. The goal is to find a safe and effective dose and see if the drug can shrink tumors. About 490 participants will take p…

This study tested whether taking the drug abiraterone on an on-and-off schedule could help men with advanced prostate cancer respond to the drug for a longer time. Nineteen men with metastatic castration resistant prostate cancer who already had a good response to abiraterone wer…

This study tested whether giving a higher dose of radiation (up to 81 Gy) to men with high-risk prostate cancer that hasn't spread could help keep the cancer from coming back. About 250 men took part, and all also received hormone therapy. Researchers tracked side effects and can…

This study tests whether using MRI to guide a radiation boost to visible prostate tumors is feasible and safe. Forty men with localized prostate cancer will receive the targeted boost before or after standard whole-gland radiation. They will be followed for up to 5 years to check…

This early-phase trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 120 people with various canc…

This study tests a gel called SpaceIT that is injected between the prostate and rectum before radiation therapy for prostate cancer. The gel creates space to reduce radiation reaching the rectum, aiming to prevent side effects. About 230 men with low- to intermediate-risk prostat…

This study tests whether a daily high-dose omega-3 supplement (fish oil) can slow the rise of PSA levels in men whose prostate cancer has returned after initial treatment. About 40 men with a rising PSA but no visible spread will take either the supplement or a placebo for one ye…

This large study is testing whether adding a radioactive drug called radium-223 to standard chemotherapy helps men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if the combination helps patients live longer than chemotherapy alon…

This study aimed to see if a shorter, less expensive MRI (using only two types of images) could find prostate cancer as well as the standard longer MRI. The researchers planned to compare the results with tissue samples from surgery. However, the study was withdrawn before any pa…

This study looks at the tears and blood of 75 men to find differences between those with and without prostate cancer. The goal is to develop a simple test that can tell aggressive prostate cancer from slow-growing forms. Participants provide a tear sample during a clinic visit.

This study tests a radioactive tracer called 18F-DCFPyL to see if it can better find prostate cancer that has spread or come back after treatment. About 360 men with high-risk or recurrent prostate cancer will get a PET/CT scan using this tracer. The goal is to improve how doctor…

This study tests whether a new radioactive tracer called 18F-DCFPyL can better detect where prostate cancer has spread in the body compared to a standard tracer. About 96 adults with metastatic prostate cancer will receive both types of scans and be followed for one year. The goa…

This study tests a special PET/CT scan that targets a protein (PSMA) on prostate cancer cells to see if it can better detect aggressive prostate cancer compared to the standard PSA blood test. About 150 men with elevated PSA levels will receive the scan before their routine prost…

This study tests a new type of PET scan that uses a radioactive tracer (64Cu-SAR-bisPSMA) to find prostate cancer that has come back after initial treatment. About 220 men with rising PSA levels will receive the tracer and be scanned. The goal is to see how well this scan detects…

This early-phase study tests a new PET imaging agent (89Zr-DFO-YS5) designed to find a protein called CD46 on prostate cancer cells in men with advanced, treatment-resistant prostate cancer. About 30 participants will receive the agent and undergo PET scans to see if it can accur…

This study looks at whether MRI can find prostate cancer earlier in men with BRCA1 or BRCA2 gene mutations, who have a higher risk of aggressive prostate cancer. Sixty men aged 50 and older will get an MRI and then a biopsy to see if the MRI is accurate. The goal is to improve ea…

This study looks at whether a special PET scan using PYLARIFY can safely and accurately find prostate cancer that has spread outside the prostate gland in men with a certain type of early-stage prostate cancer. About 274 men will get one injection of PYLARIFY followed by a full-b…

This study is testing a new blood test that looks at genetic material (RNA) from tiny particles in the blood (exosomes) to diagnose prostate cancer. The goal is to see if this test is more accurate than current methods, potentially reducing the need for invasive biopsies. The stu…

This study compares two types of urine samples—prostatic fluid and post-massage urine—to see which one better predicts whether a prostate biopsy will find cancer. About 243 men scheduled for a prostate biopsy will provide both samples, and researchers will check which sample's ma…

This study looks at whether a special PET scan called Axumin can find prostate cancer that has returned after treatment, in cases where another common scan (PSMA PET) found nothing. About 50 adults with rising PSA levels and a negative PSMA scan will get an Axumin PET. The goal i…

This study looks at the best time to use a special PET scan (rhPSMA-7.3) to find prostate cancer that has come back after surgery. Men with a rising PSA level after prostate removal will get one or two scans to see where the cancer is hiding. The goal is to catch the cancer early…

This study looks at whether a new screening method using PHI blood test and mp-MRI scans can find prostate cancer earlier in men with DNA repair gene (DRG) mutations. Current screening often misses aggressive cancers in these men. The goal is to catch more cancers early, when the…

This study aims to improve early detection of prostate cancer by adding MRI and a risk calculator to the standard PSA blood test. Researchers will enroll 4,500 men aged 55-65 in Italy to see if this approach finds more aggressive cancers while reducing unnecessary biopsies. The g…

This early-phase study tests a new radioactive tracer called TRDC002 to help doctors see where prostate cancer has returned or spread. Six adults with PSMA-positive recurrent or metastatic prostate cancer will receive the tracer and then have a PET/CT scan. The goal is to find th…

This study tests whether analyzing ultrasound images with computer software can help doctors find prostate cancer more accurately during a targeted biopsy. About 464 men aged 55 and older with suspected prostate cancer will take part. The approach compares the new ultrasound-base…

This study tested a special PET scan (18F-DCFPyL) to see if it can find cancer spread that standard scans miss in men with castration-resistant prostate cancer starting enzalutamide. About 50 men with no or few signs of spread on regular scans took part. The goal was to see if th…

This study compares two biopsy methods—MRI fusion and micro-ultrasound—to see which better detects aggressive prostate cancer. It involves 29 men with suspected cancer or on active surveillance. The goal is to find a more accessible screening option for underserved communities.…

This study tests a new software that combines MRI and ultrasound images in real time to help doctors more accurately detect and locate aggressive prostate cancer during biopsy. About 100 men scheduled for a standard prostate biopsy will take part. The goal is to improve early dia…

This study tests whether adding a PSMA PET scan helps doctors better diagnose significant prostate cancer in men whose MRI results are unclear or negative. About 660 men with no prior prostate cancer or biopsy will be randomly assigned to receive either standard care or an additi…

This study explores how diet, physical activity, and other lifestyle factors influence the risk of prostate cancer in over 2000 men. Researchers aim to identify biological markers that can predict which men are at higher risk. The goal is to use these markers to create personaliz…

This study looks at whether a 16-week home exercise program can help Black and Hispanic patients with breast, colorectal, or prostate cancer become more active while on chemotherapy. Participants will either do supervised or unsupervised aerobic and resistance exercises, or simpl…

This study compares two types of internal radiation boost (HDR vs LDR brachytherapy) given after external beam radiation for intermediate- or high-risk prostate cancer. The goal is to see which method better controls cancer while causing fewer side effects and preserving quality …

This study tests if robot-assisted prostate removal can be safely done as outpatient surgery for men with localized prostate cancer. Twenty patients will be followed for one month to see if they can avoid an overnight hospital stay. The goal is to make recovery more convenient an…

This study tests whether using a bedside lung ultrasound during robotic prostate or bladder surgery helps doctors set the ventilator more precisely to prevent lung collapse and overinflation. About 88 adults with mild or no lung disease will be randomly assigned to standard care …

This study tests whether a gentle electrical current applied to specific skin spots (AcuTENS) can reduce pain and anxiety during a prostate biopsy. About 53 men having their first biopsy will receive either real or fake TENS alongside standard numbing. The goal is to see if this …

This study compares two types of radiation therapy—proton beam therapy and IMRT—for men with low- or intermediate-risk prostate cancer. Both treatments aim to cure the cancer by targeting the prostate while sparing healthy tissue, but they may cause different side effects like bo…

This study tests a new way to give radiation for prostate cancer that aims to reduce side effects. Instead of giving the same dose to the whole prostate, the tumor gets a higher dose and the rest of the prostate gets a lower dose. The study includes 20 men with intermediate-risk …

This study compares two types of internal radiation (brachytherapy) for men with early-stage prostate cancer. The goal is to see which method better preserves quality of life, especially urinary function. About 140 men with favorable or low-risk intermediate prostate cancer will …

This study tests a 4-month community program called Men Moving Forward for African-American men who have finished prostate cancer treatment. Participants attend two sessions each week to improve their diet and physical activity. The goal is to help them build muscle, lose fat, an…

This study tests whether live exercise coaching plus a personalized digital app can improve quality of life for cancer survivors. About 146 adults with breast, lung, prostate, colorectal, or other cancers who had treatment in the last year will use the program for 18 months. Rese…

This study looks at whether exercise, supportive counseling, and a stimulant drug (methylphenidate) can help reduce severe fatigue in men with prostate cancer who are receiving radiation and hormone therapy. About 175 participants will try different combinations of these treatmen…

This study tests whether a culturally adapted strength training program, done together with a caregiver, is feasible and beneficial for Hispanic prostate cancer survivors and their caregivers. The program involves remote group exercise classes over 3 months, with a 3-month follow…

This study looks at whether giving men a deeper level of muscle relaxation during robotic prostate surgery can lower the pressure in the belly during the operation and reduce pain afterward. About 139 men having robotic prostatectomy will be randomly assigned to either deep or mo…

This study tests whether acupuncture can reduce frequent nighttime urination (nocturia) in prostate cancer survivors. About 60 survivors will receive 10 acupuncture sessions over several weeks. Researchers will check if acupuncture is practical and helpful for improving sleep, mo…

This study tests whether a pelvic floor muscle exercise program, taught by a physical therapist before and after prostate removal surgery, can help prevent or shorten urine leakage. Researchers will track how many of the 32 participants stick with the program and report their sat…

This study looks at whether giving a numbing injection (TAP block) at the start or end of robotic prostate surgery helps men feel less pain afterward. About 94 men with prostate cancer will take part. The goal is to find the best timing to reduce pain and the need for strong pain…

This study compares two pain control methods after robotic prostate removal: one using opioids and one using only non-opioid medicines like ketamine, ketorolac, and acetaminophen. About 100 men aged 40-75 with prostate cancer will take part. The goal is to see if the opioid-free …

This study tests whether a gel called SpaceOAR Vue, placed between the prostate and the bowel, can reduce bowel side effects in men receiving high-dose radiation for prostate cancer. About 500 men with intermediate-risk prostate cancer will be randomly assigned to get radiation w…

This study tests a new surgical technique called NeuroSAFE during robotic prostate removal for prostate cancer. The goal is to see if it helps men keep erectile function and urinary control better than standard surgery. About 407 men who are potent and continent will take part. T…

This study was designed to observe and measure certain proteins called chemokines in the blood, urine, and tumors of people with prostate cancer. The goal was to see how these protein levels change over time and relate to the disease. However, the study was withdrawn before any p…

This study follows nearly 2,000 men with newly diagnosed prostate cancer to see if certain genes make the cancer more likely to spread. Researchers collect blood or tissue samples to analyze genetic markers. The goal is to better understand who is at higher risk, not to test a ne…

This study looks at how screening for social needs (like food, housing, and transportation) and providing community health worker support can improve quality of life for Black breast and prostate cancer survivors in Washington, D.C. It also tests anti-racism training for healthca…

This early-stage study tests whether a special MRI scan using a safe, injected substance (hyperpolarized bicarbonate) can measure acidity levels in prostate tumors. The goal is to see if this imaging method is feasible and safe in a small group of men scheduled for prostate remov…

This study collects tissue, blood, and fluid samples from men with prostate conditions (including those without cancer) to help researchers understand what causes prostate cancer, why some cancers are more aggressive, and why they respond differently to treatments. Up to 5,290 pa…

This study looks at a new approach where cancer doctors offer genetic testing directly to patients with ovarian, prostate, or pancreas cancer, instead of referring them to a genetic counselor. The goal is to see how patients feel about this method and if it changes their distress…

This study aims to find non-invasive biomarkers (signals in blood or urine) that can help doctors monitor prostate cancer progression without relying solely on repeated biopsies. It will follow 500 men with low-to-high risk prostate cancer who are receiving standard care, collect…

This study follows 304 men in Martinique diagnosed with prostate cancer from 2020 onward. Researchers use digital questionnaires to track changes in quality of life, focusing on sexual and urinary issues. The goal is to gather data that can help reduce health disparities and impr…

This study looks at 30 men with high-risk prostate cancer who are getting standard radiation and hormone therapy. Researchers want to see if special scans and genetic tests can predict early on whether the treatment is working. The goal is to better understand which patients migh…

This study looks at whether the Decipher tumor test can predict aggressive prostate cancer with the same accuracy in African-American men as in non-African-American men. The test was developed mainly from samples of European descent, but African-American men have higher rates of …

This study aims to improve how total-body PET scans work for people with prostate cancer, breast cancer, or neuroendocrine tumors. Researchers will collect extra data from FDA-approved imaging agents during routine scans. Only 9 participants are needed, and the goal is to learn m…

This study follows 490 Brazilian men with low-risk prostate cancer who choose active surveillance instead of immediate treatment. Researchers track how often the cancer becomes more serious and how long patients can avoid treatment. The goal is to see if this monitoring approach …

This study follows 200 men with prostate cancer who are receiving hormone therapy (androgen deprivation therapy) for at least 6 months. Researchers want to understand how this treatment affects the heart, including changes in heart function and the risk of heart failure. They wil…

This study looks at ways to help people who have inherited gene changes that raise cancer risk. It tests if certain tools can help them follow doctor guidelines for managing their cancer risk and share their genetic results with family members. About 720 adults with these gene ch…

This study looks at whether a 2-minute animated video can help men with early-stage prostate cancer better understand their treatment choices. About 400 men will watch the video and then pick from surveillance, focal therapy, or standard treatment. Researchers will track their ch…

This study tests whether a special PET/CT scan, done before surgery to remove the prostate, can predict if prostate cancer will come back. About 175 men with high-risk prostate cancer will get the scan, then have their prostate removed. Researchers will follow them for 5 years to…

This study collects DNA from over 21,000 people with different cancers (like breast, colon, and lung) in New York. Researchers will look for inherited gene changes that might be linked to cancer. The goal is to find clues for future studies, not to test a treatment.

This study tests whether a new smartphone app can help African American men learn about prostate cancer and complete a home-based PSA test. About 80 men aged 55 to 69 from Oklahoma who haven't had a PSA test in the last two years will use either the new app or an existing governm…

This study tests a program that helps doctors follow guidelines when ordering imaging tests for prostate cancer. About 58 VA doctors and staff took part. The goal is to reduce inappropriate scans and ensure the right tests are used for each patient.

This study follows 7,500 men aged 50-74 to see if a modern screening program using PSA, a biomarker blood test, and MRI scans leads to fewer prostate cancer deaths compared to standard PSA testing alone. Participants were previously invited for screening, and researchers track th…

This study aimed to compare two different physical therapy programs for men who still have urine leakage more than a year after prostate cancer surgery. One program used standard Kegel exercises, while the other focused on whole-body posture and stability. The study was withdrawn…

This study collects tissue and blood samples from 156 people with advanced prostate, kidney, or bladder cancers. Researchers analyze these samples to find genetic markers that predict how well different treatments work. Participants undergo a biopsy of a growing tumor before star…

This study looks at how often bowel control problems happen in prostate cancer survivors who had a specific type of radiation therapy. Researchers will check if the radiation dose to the anal muscles is linked to the severity of these problems. About 200 people who finished treat…

This study tests a special needle with a tiny tracking device inside, like a mini GPS, to help doctors find hard-to-see tumors during biopsies or ablation procedures. About 3,900 adults with certain cancers or growths will take part. The goal is to see if this tool can place the …

This study looks at whether a 12-week survivorship program can be added to the usual follow-up care for men with advanced prostate, kidney, bladder, testicular, or penile cancer. Researchers will ask 72 men about their experience to see if the program is practical and helpful. Th…

This study follows about 178 people who previously received an experimental AvenCell CAR-T cell therapy for blood cancers or prostate cancer. Researchers will monitor participants for years to check for delayed side effects, such as new cancers, nerve disorders, or severe infecti…

This early-phase study tests a new radioactive tracer called 18F-FluorThanatrace to see how well it can detect PARP-1 activity in prostate cancer tumors. About 30 men with prostate cancer who are scheduled for surgery will get a PET/CT scan with this tracer. The scan results will…

This study looks at how two different prostate cancer medications, darolutamide and enzalutamide, affect thinking skills like memory and attention. About 111 men with advanced prostate cancer will take one of the two drugs and complete computer-based brain tests over time. The go…

This study looks at why some prostate cancer survivors have trouble with thinking and memory. Researchers will collect information from 200 survivors to see how anxiety, depression, sleep problems, and other factors may play a role. The goal is to better understand these issues, …

This study follows about 1,000 prostate cancer patients who are starting treatment with ORGOVYX. Researchers want to see how safe and effective the drug is in routine medical practice, and how patients' quality of life and disease change over time. No new treatment is given—just …

This study looks at men aged 40-69 who have certain gene mutations (BRCA1, BRCA2, or mismatch repair) that raise their risk for prostate cancer. Researchers give annual PSA tests to see how often cancer is found compared to men without these mutations. The goal is to learn more a…

This study is a registry that collects information on 500 men with metastatic castration-resistant prostate cancer who are treated with PSMA theranostics. The main goal is to see how many men have a significant drop in PSA levels after treatment. Researchers will also track side …

This study looks at whether giving hormone therapy to men whose prostate cancer has returned can make cancer cells more visible on a special PET scan. About 9 men will take a standard hormone pill for a few weeks and then get a scan to see if new spots light up. The goal is to le…

This study looks at whether a man's genetic profile can help doctors decide who should be screened for prostate cancer. About 300 men aged 55-69 will have their genes checked and those with higher genetic risk will be offered a prostate biopsy. The goal is to see if this approach…

This study looks at whether giving antibiotics before a prostate biopsy (done through the skin between the testicles and anus) is really needed to prevent infections. Researchers will compare infection rates in 300 men who either receive or skip preventive antibiotics. The goal i…

This study looks at whether hormone therapy (like Lupron or Casodex) changes thinking abilities in men aged 65 and older with prostate cancer. Researchers will compare men starting or already on hormone therapy with those not on it. The goal is to understand cognitive changes, no…

This study looks at how prostate cancer changes after radiation treatment using special MRI scans. Researchers want to see if MRI can help doctors manage treatment better and faster. About 120 men with prostate cancer who are getting radiation will take part. The goal is to learn…

This study looks at how a person's sense of coherence—their ability to cope with stress and stay positive—affects their quality of life after radiation therapy for prostate cancer. About 250 men will fill out questionnaires before, right after, and one year after treatment. The g…

This study tests whether artificial intelligence (AI) can help doctors outline the prostate on ultrasound images during a type of radiation treatment called brachytherapy for prostate cancer. Researchers will compare AI-assisted outlines to those done manually, measuring accuracy…

This study planned to give men with prostate cancer the drug ruxolitinib for 28 days before their prostate removal surgery. Researchers wanted to see how the drug changes immune cells in the tumor and blood. However, the study was withdrawn before any participants were enrolled, …

This study was designed to learn how much information people can recall about their own cancer screening and diagnosis. Researchers planned to see if giving extra time or resources helps people remember more accurately. The study was withdrawn before enrolling any participants, s…

This large study looks at the DNA of nearly 24,000 men with prostate cancer to find inherited genes that increase risk. It focuses on younger men and those with a family history, where genetics likely play a bigger role. The goal is to understand why some families have higher rat…

This study looks at the financial burden (called financial toxicity) that people face after having robotic surgery for prostate, bladder, or kidney cancer. Researchers will ask 120 patients to fill out questionnaires about their expenses, travel costs, and support needs. The goal…

This study looks at whether a special type of MRI, called RSI-MRI, can predict how well high-risk prostate cancer patients respond to radiation and hormone therapy. About 100 adult men with high-risk, localized prostate cancer will get an RSI-MRI scan before and during treatment.…

This study looks at whether detailed analysis of MRI scans (called radiomics) can help doctors better predict how aggressive a prostate cancer is and whether it will come back soon after surgery. Researchers will study 125 patients who have prostate MRI before surgery. The goal i…

This study looks at whether a home-based treadmill walking program can change certain markers of prostate cancer progression in men with low-risk disease who are not receiving active treatment. About 36 men on active surveillance will either follow a prescribed exercise plan or c…

This study tests whether a special type of PET scan, called PSMA PET, can track prostate cancer more accurately than usual scans like CT or bone scans. About 58 men with progressive or newly diagnosed prostate cancer will get PSMA PET scans over time. The goal is to see if change…

This study looks back at the results of robotic prostate removal surgery in over 1,500 men with prostate cancer. Researchers aim to understand patient traits and how they relate to surgery success, cancer return, and survival. The goal is to improve future treatment decisions.

This study looks at whether a genetic test called the Genomic Prostate Score (GPS) can help doctors better choose men for focal therapy, a treatment that targets only the cancer while sparing healthy prostate tissue. Researchers will review past data and tissue samples from 241 m…

This study aimed to collect prostate tissue samples from men undergoing brachytherapy for prostate cancer. The goal was to bank these samples for future research on how radiation affects the prostate. However, the study was withdrawn before enrolling any participants.

This study analyzed data from 3,350 men with early-stage prostate cancer who chose watchful waiting (no immediate treatment). Researchers looked at biological, pathological, and clinical markers to find which factors best predict how the disease will progress. The goal is to help…

This study tests a method called KIM that uses gold markers to track prostate movement during radiation therapy. If the prostate moves more than 3mm, the radiation beam stops and is repositioned. The goal is to see if this technique is feasible in 100 men with prostate cancer rec…

This study looks at whether a substance in the blood called chromogranin A (CgA) can help predict if prostate cancer will come back after radiation therapy. Researchers will measure CgA levels before, during, and after treatment in 118 men with prostate cancer. The goal is to see…

This study looks at whether breath tests, blood tests for DNA, and special scans can predict how prostate cancer and healthy tissues respond to a precise type of radiotherapy called SBRT. Researchers will follow 60 men with low- or intermediate-risk prostate cancer for up to 2 ye…

This study looks at whether a simple blood test can predict memory and thinking problems in men with prostate cancer who are receiving hormone therapy (ADT). Researchers will track 32 men over time, testing their memory and measuring a blood marker linked to Alzheimer's risk. The…

This study explores whether advanced MRI scans can detect how prostate cancer and nearby healthy tissues respond to radiation therapy while treatment is still ongoing. Researchers will enroll 38 men with prostate cancer who are scheduled for external beam radiation. The goal is t…

This study looks at how Spanish-speaking Latiné men who have had prostate cancer surgery make decisions about their health after treatment. Researchers will talk to 55 people in focus groups to understand their unique cultural and language needs. The goal is to create better educ…

This study looks at whether removing lymph nodes during prostate removal surgery helps prevent cancer from coming back in men with intermediate-risk prostate cancer. About 3,650 men will be randomly assigned to have lymph nodes removed or not. The goal is to see if the extra surg…

This study tests a new system that helps doctors better understand the needs of older adults with cancer. The system combines checks on aging, mental health, lifestyle, and social factors. About 35 patients aged 65 and older will try it during their first cancer visit. The goal i…

This study follows about 64,000 adults who grew up on farms to see if early exposure to pesticides and other farm-related factors is linked to cancer. Participants fill out a questionnaire and may provide blood or other samples. The goal is to understand how childhood agricultura…

This study looks at whether artificial intelligence (AI) can help doctors quickly and accurately find men with prostate cancer who are eligible for a clinical trial. Researchers will use an AI tool to rank patients by how likely they are to qualify, then compare the results to tr…

This long-term study aims to understand why farmers and their families may have higher risks for certain cancers, like prostate cancer and lymphoma. Researchers are following about 90,000 pesticide applicators and their spouses in Iowa and North Carolina, collecting information o…